Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib

Anticancer Research

Volumn 35, Issue 3, 2015, Pages 1803-1808

  Godin, Corinne ^a,b   Louandre, Christophe ^a,b   Bodeau, Sandra ^a   Diouf, Momar ^b   Saidak, Zuzana ^a   Conte, Marie Alix ^a   Chauffert, Bruno ^b   Barbare, Jean Claude ^b   Barget, Nathalie ^c   Trinchet, Jean Claude ^c,d,e   Ganne, Nathalie ^c,d,e   Galmiche, Antoine ^a,b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITÉ PARIS 13   (France)

^e Université Paris 13   (France)

Author keywords

Hepatocellular carcinoma; M30; M65; Programmed cell death; Sorafenib

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CYTOKERATIN 18; DOXORUBICIN; M30 ANTIGEN; M65 ANTIGEN; SORAFENIB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; VASCULOTROPIN RECEPTOR;

AGED; APOPTOSIS; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER PATIENT; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR NECROSIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; NECROSIS; PATHOLOGY;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KERATIN-18; LIVER NEOPLASMS; MALE; NECROSIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84924940121     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Forner A, Llovet JM and Bruix J: Hepatocellular Carcinoma. Lancet 379: 1245-1255, 2012.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak W Y, Pan H, Burock K, Zou J, Voliotis D and Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
4. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56: 908-943, 2012.
5. Galmiche A, Chauffert B and Barbare JC: New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett 346: 159-162, 2014.
6. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumour angiogenesis, and induces tumour cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858, 2006.
7. Galmiche A, Ezzoukhry Z, François C, Louandre C, Sabbagh C, Nguyen-Khac E, Descamps V, Trouillet N, Godin C, Regimbeau JM, Joly JP, Barbare JC, Duverlie G, Mazière JC and Chatelain D: BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. Mol Cancer Res 8: 1116-1125, 2010.
8. Fernando J, Sancho P, Fernández-Rodriguez CM, Lledó JL, Caja L, Campbell JS, Fausto N and Fabregat I: Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J Cell Physiol 227: 1319-1325, 2012.
9. Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazière JC, Chauffert B and Galmiche A: Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer 133: 1732-1742, 2013.
10. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd and Stockwell BR: Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149: 1060-1072, 2012.
11. Coriat R, Nicco C, Chéreau C, Mir O, Alexandre J, Ropert S, Weill B, Chaussade S, Goldwasser F and Batteux F: Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther 11: 2284-2293, 2012.
12. Eguchi A, Wree A and Feldstein AE: Biomarkers of liver cell death. J Hepatol 60: 1063-1074, 2014.
13. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J and Gores GJ: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711, 2008.
14. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, Marberger M, Bivén K, Shoshan MC and Linder S: Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64: 1751-1756, 2004.
15. Waidmann O, Köberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiß M, Kronenberger B and Piiper A: Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. J Hepatol 59: 769-779, 2013.